A New Supplement for the Immune Response to HPV Infection

Ellagic Acid and Annona Muricata May Modulate the Immune Response to High Risk HPV Infection. A Randomized, Controlled Trial.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02263378

Enrollment

Registered

2014-10-13

Start date

2014-09-30

Completion date

2016-03-31

Last updated

2016-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV Infection

Keywords

HPV, L-SIL

Brief summary

The purpose of this study is to evaluate whether a supplement in which ellagic acid plus annona muricata are combined, may modulate the immune response to high risk HPV infection. Sixty women will be enrolled in a randomized, controlled study, having a histological diagnosis of L-SIL correlated with high rish HPV types infection. Main outcome measure is the activation of onco suppressor protein by the supplement and secondary outcome is the clearance of HPV infection in the treated group.

Interventions

DRUGellagic acid + annona muricata

pills

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 50 Years

Healthy volunteers

Inclusion criteria

* women with high risk HPV infection * histological diagnosis of L-SIL

Exclusion criteria

* women with no high risk HPV infection * women without histological diagnosis of L-SIL

Design outcomes

Primary

Measure	Time frame
variation of onco suppressor protein expression from basal values. The expression variations are represented by the different percentage of positive cells	6 months

Secondary

Measure	Time frame
clearance of the HPV infection	6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026